.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the general public market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the symbol "BIOA," according to documents submitted along with the Securities and also Exchange Commission. The business has actually certainly not publicly discussed an anticipated monetary quantity for the offering.The clinical-stage business boasts lead prospect azelaprag, a by mouth delivered small molecule slated to get into period 2 screening in combination along with semaglutide-- offered through Novo Nordisk under brand Wegovy for fat burning-- in the very first one-half of following year. Semaglutide is likewise marketed as Ozempic and Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually developed to mix effectively along with GLP-1 medications, enhancing weight loss while protecting muscle mass. The investigational medication was discovered to become well-tolerated one of 265 individuals throughout 8 phase 1 tests, depending on to BioAge.Formerly, BioAge garnered the support of Lilly to manage a test blending azelaprag along with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro and also Zepbound for effective weight loss. The partners are actually currently carrying out a period 2 trial of azelaprag and also tirzepatide, along with topline end results expected in the 3rd quarter of 2025.The biotech is actually additionally preparing a blood insulin sensitivity proof-of-concept test determining azelaprag as a monotherapy in the very first fifty percent of next year to assist prospective indicator growth. Moreover, the provider prepares to inquire the FDA for authorization in the 2nd one-half of 2025 to introduce human screening for an NLRP3 prevention targeting metabolic ailments as well as neuroinflammation.BioAge's foreseed transfer to the public market follows a mild uptick in planned biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the recent IPO yard is a "blended picture," with high quality firms still debuting on the general public markets, merely in minimized amounts, according to PitchBook.